Previous studies have demonstrated mTOR pathway activation in two thirds of neuroblastoma patients, with AKT and mTOR phosphorylation in primary neuroblastoma, and this pathway activation correlated with reduced event-free and overall survival [50–52]. The gene discussed is MTOR; the disease is neuroblastoma.